Document:

Grant of Security Interest Agmt

 Exhibit 10.32 
 GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY 

THIS GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY is made as of November 17, 2010 (as amended,
restated, supplemented and/or modified from time to time, this “Grant”), by ANALYTICA INTERNATIONAL, INC., a Florida corporation (the “Grantor”), in favor of LV ADMINISTRATIVE SERVICES, INC., a Delaware corporation,
as administrative and collateral agent for the Lenders (the “Secured Party”). 
 W I T N E S S E T H

 WHEREAS, as of the date hereof, and pursuant to that certain Term Loan and Security Agreement
dated as of November 17, 2010 (as amended, restated, supplemented and/or modified from time to time, the “Biovest Security Agreement”) by and among Biovest International, Inc. (“Biovest”), the Lenders party
thereto and the Secured Party, Biovest has made and delivered to the Lenders certain Secured Term A Notes in an aggregate principal amount of $24,900,000 (“Term A Notes”), and certain Secured Term B Notes in an aggregate principal
amount of $4,160,000 (“Term B Notes” and together with the Term A Notes, the “Biovest Term Notes”); 
 WHEREAS, as of the date hereof, and pursuant to that certain Term Loan and Security Agreement dated as of November 17, 2010 (as amended, restated, supplemented and/or modified from time to
time, the “Accentia Security Agreement”) by and among Accentia Biopharmaceuticals, Inc. (“Accentia”), the Lenders party thereto and the Secured Party, Accentia has made and delivered to the Lenders certain Secured
Term Notes in the aggregate principal amount of $8,800,000 (the “Accentia Term Notes”); 

WHEREAS, pursuant to that certain Analytica Guaranty dated the date hereof, Grantor has guaranteed the obligations
of Accentia under the Biovest Security Agreement (as limited) and the Accentia Security Agreement; 

WHEREAS, the Grantor shall derive substantial benefit from the financial accommodations provided to Accentia under
the Biovest Term Notes and the Accentia Term Notes; 
 WHEREAS, the Grantor (1) has adopted, used
and is using the trademarks reflected in the trademark registrations and trademark applications in the United States Patent and Trademark Office more particularly described on Schedule 1 annexed hereto as part hereof (the
“Trademarks”), (2) has registered or applied for registration in the United States Patent and Trademark Office of the patents more particularly described on Schedule 2 annexed hereto as part hereof (the
“Patents”), (3) has adopted, used and is using the copyrights and copyright licenses (whether registered or unregistered with the United States Copyright Office) more particularly described on Schedule 3 annexed hereto
as part hereof (the “Copyrights”), and (4) has adopted, used and is using all other intellectual property not covered by the foregoing, including any and all of the following: (i) patents, (ii) trademarks,
(iii) copyrights, (iv) patent licenses, (v) copyright licenses, (vi) trade secrets, (vii) all intellectual property rights in or to software, databases and data collections, (viii) know how, and (ix) all domain
names, together with all registrations and applications for registration for any of the foregoing (the 

 
“Miscellaneous Property” and collectively with the Trademarks, Patents and Copyrights, the “Intellectual Property”); and 

WHEREAS, the Grantor wishes to confirm its grant to the Secured Party of a security interest in all right, title
and interest of the Grantor in and to the Intellectual Property, and all proceeds thereof, together with the business as well as the goodwill of the business symbolized by, or related or pertaining to the Intellectual Property, and the customer
lists and records related to the Intellectual Property and all causes of action which may exist by reason of infringement of any of the Intellectual Property (collectively, the “Collateral”), to secure the satisfaction and discharge
of all of Grantor’s obligations under the Analytica Security Agreement and the Analytica Guaranty (collectively, the “Grantor Obligations”). 

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged: 

1.        Capitalized terms used in this Grant but not otherwise defined herein
shall have the meanings ascribed to them in the Biovest Security Agreement. 

2.        The Grantor does hereby grant to the Secured Party a security interest
in the Collateral to secure the full and prompt payment, performance and observance of the Grantor Obligations. 

3.        The Grantor agrees to perform, so long as the Analytica Security
Agreement and the Analytica Guaranty are in effect, all acts deemed necessary or desirable by the Secured Party to permit and assist it, at the Grantor’s expense, in obtaining and enforcing the Intellectual Property in any and all countries.
Such acts may include, but are not limited to, execution of documents and assistance or cooperation in legal proceedings. The Grantor hereby appoints the Secured Party as the Grantor’s attorney-in-fact to execute and file any and all
agreements, instruments, documents and papers as the Secured Party may determine to be necessary or desirable to evidence the Secured Party’s security interest in the Intellectual Property or any other element of the Collateral, all acts of
such attorney-in-fact being hereby ratified and confirmed. 

4.        The Grantor acknowledges and affirms that the rights and remedies of
the Secured Party with respect to the security interest in the Collateral granted hereby are more fully set forth in the Analytica Security Agreement and the Analytica Guaranty, and the rights and remedies set forth herein are without prejudice to,
and are in addition to, those set forth in the Analytica Security Agreement and the Analytica Guaranty. In the event that any provisions of this Grant are deemed to conflict with the Analytica Security Agreement or the Analytica Guaranty, the
provisions of the Analytica Security Agreement or the Analytica Guaranty, as applicable, shall govern. 

5.        The Grantor hereby authorizes the Secured Party to file all such
financing statements or other instruments to the extent required by the UCC and agrees to execute all such other documents, agreements and instruments as may be required or deemed necessary by the Secured Party, in each case for purposes of
effecting or continuing Secured Party’s security interest in the Collateral. 

 6.        This Grant may be executed
in any number of counterparts, each of which shall be an original, but all of which shall constitute one instrument. It is understood and agreed that if facsimile copies of this Grant bearing facsimile signatures are exchanged between the parties
hereto, such copies shall in all respects have the same weight, force and legal effect and shall be fully as valid, binding, and enforceable as if such signed facsimile copies were original documents bearing original signature. 

[remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the undersigned have caused this Grant of Security
Interest in Intellectual Property to be executed as of the day and year first above written. 
  

			
	 ANALYTICA INTERNATIONAL, INC.

		
	 By:
	 	           /s/ Samuel S.
Duffey

			
	 Name:
	 	      Samuel S. Duffey

	 Title:
	 	      President

  

			
	 ACCEPTED and AGREED:

	
	 LV ADMINISTRATIVE SERVICES, INC.

		
	 By:
	 	 /s/ Patrick
Regan

			
	 Name:
	 	 Patrick Regan

			
	 Title:
	 	 Authorized Signatory

 

 SCHEDULE 1 
 Trademarks 
 None 

 SCHEDULE 2 
 Patents 
 None 

 SCHEDULE 3 
 Copyrights 
 NoneGrant of Security Interest in Intellectual Property

 Exhibit 10.33 
 GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY 

THIS GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY is made as of November 17, 2010 (as amended,
restated, supplemented and/or modified from time to time, this “Grant”), by BIOVEST INTERNATIONAL, INC., a Delaware corporation (“Grantor”) in favor of LV ADMINISTRATIVE SERVICES, INC., a Delaware corporation, as
administrative and collateral agent for the Lenders (the “Secured Party”). 
 W I T N E S S E T H

 WHEREAS, as of the date hereof, and pursuant to that certain Term Loan and Security Agreement
dated as of November 17, 2010 (as amended, restated, supplemented and/or modified from time to time, the “Security Agreement”) by and among the Grantor, the Lenders party thereto and the Secured Party, Grantor has made and
delivered to the Lenders certain Secured Term A Notes in an aggregate principal amount of $24,900,000 (“Term A Notes”), and certain Secured Term B Notes in an aggregate principal amount of $4,160,000 (“Term B Notes”
and together with the Term A Notes, the “Term Notes”); 
 WHEREAS, pursuant to the
Security Agreement, Grantor has granted a security interest and lien on all of its assets to the Lenders; 

WHEREAS, the Grantor (1) has adopted, used, is using, or intends to use the trademarks reflected in the
trademark registrations and trademark applications more particularly described on Schedule 1 (whether registered or unregistered with the United States Patent and Trademark Office) annexed hereto as part hereof (the
“Trademarks”), (2) has registered or applied for registration in the United States Patent and Trademark Office of the patents more particularly described on Schedule 2 annexed hereto as part hereof (the
“Patents”), (3) has adopted, used and is using the copyrights and copyright licenses (whether registered or unregistered with the United States Copyright Office) more particularly described on Schedule 3 annexed hereto
as part hereof (the “Copyrights”), and (4) has adopted, used and is using all other intellectual property not covered by the foregoing, including any and all of the following: (i) patents, (ii) trademarks,
(iii) copyrights, (iv) patent licenses, (v) copyright licenses, (vi) trade secrets, (vii) all intellectual property rights in or to software, databases and data collections, (viii) know how, and (ix) all domain
names, together with all registrations and applications for registration for any of the foregoing (the “Miscellaneous Property” and collectively with the Trademarks, Patents and Copyrights, the “Intellectual
Property”); and 
 WHEREAS, the Grantor wishes to confirm its grant to the Secured Party of a
security interest in all right, title and interest of the Grantor in and to the Intellectual Property, and all proceeds thereof, together with the business as well as the goodwill of the business symbolized by, or related or pertaining to the
Intellectual Property, and the customer lists and records related to the Intellectual Property and all causes of action which may exist by reason of infringement of any of the Intellectual Property (collectively, the “Collateral”),
to secure the satisfaction and discharge of all of Grantor’s obligations under the Term Notes and the Security Agreement (collectively, the “Grantor Obligations”). 

 NOW, THEREFORE, for good and valuable consideration, receipt of which is
hereby acknowledged: 
 1.        Capitalized terms used in this Grant
but not otherwise defined herein shall have the meanings ascribed to them in the Security Agreement or the Term Notes, as applicable. 
 2.        The Grantor does hereby grant to the Secured Party a security interest in the Collateral to secure the full and prompt payment, performance and observance
of the Grantor Obligations. Notwithstanding the foregoing, the security interests in the Collateral, as provided for herein, shall terminate upon the payment in full of the Term Notes and all interest, fees, costs, charges, expenses, or other sums
payable thereunder, under the Security Agreement or any of the Ancillary Agreements (other than the Biovest Contingent Payment Agreement). 
 3.        The Grantor agrees to perform, so long as the Security Agreement and Term Notes are in effect, all acts deemed necessary or desirable by the Secured Party
to permit and assist it, at the Grantor’s expense, in obtaining and enforcing the Intellectual Property in any and all countries. Such acts may include, but are not limited to, execution of documents and assistance or cooperation in legal
proceedings. The Grantor hereby appoints the Secured Party as the Grantor’s attorney-in-fact to execute and file any and all agreements, instruments, documents and papers as the Secured Party may determine to be necessary or desirable to
evidence the Secured Party’s security interest in the Intellectual Property or any other element of the Collateral, all acts of such attorney-in-fact being hereby ratified and confirmed. 

4.        The Grantor acknowledges and affirms that the rights and remedies of
the Secured Party with respect to the security interest in the Collateral granted hereby are more fully set forth in the Security Agreement and the Term Notes, and the rights and remedies set forth herein are without prejudice to, and are in
addition to, those set forth in the Security Agreement and the Term Notes. In the event that any provisions of this Grant are deemed to conflict with the Security Agreement or the Term Notes, the provisions of the Security Agreement or the Term
Notes, as applicable, shall govern. 
 5.        The Grantor hereby
authorizes the Secured Party to file all such financing statements or other instruments to the extent required by the UCC and agrees to execute all such other documents, agreements and instruments as may be required or deemed necessary by the
Secured Party, in each case for purposes of effecting or continuing Secured Party’s security interest in the Collateral. 
 6.        This Grant may be executed in any number of counterparts, each of which shall be an original, but all of which shall constitute one instrument. It is
understood and agreed that if facsimile copies of this Grant bearing facsimile signatures are exchanged between the parties hereto, such copies shall in all respects have the same weight, force and legal effect and shall be fully as valid, binding,
and enforceable as if such signed facsimile copies were original documents bearing original signature. 

 IN WITNESS WHEREOF, the undersigned have caused this Grant of Security
Interest in Intellectual Property to be executed as of the day and year first above written. 
  

			
	 BIOVEST INTERNATIONAL, INC.

		
	 By:
	 	 /s/ David
Moser

			
	 Name:
	 	 David Moser

	 Title:
	 	 Secretary

  

			
	 ACCEPTED and AGREED:

	
	 LV ADMINISTRATIVE SERVICES, INC.

		
	 By:
	 	 /s/ Patrick
Regan

			
	 Name:
	 	 Patrick Regan

			
	 Title:
	 	     Authorized Signatory

 SCHEDULE 1 
 Trademarks 
  

											
	Country	  	Trademark	  	 Registration

No.
	  	
Registration

Date
	  	Serial No.	  	Filing Date
	
	 
	  
 US
	  	BIOVEST (Class 5)	  	3,794,981	  	5/25/10	  	78/449,930	  	07/13/2004
	 EU
	  	  
 BIOVEST (Classes 5, 9, and 42)
	  	004239422	  	3/2/2006	  	004239422	  	01/13/2005
	 US
	  	  
 BIOVEST (Class 9)
	  	3,716,935	  	11/24/2009	  	78/449,968	  	07/13/2004
	 US
	  	  
 BIOVEST (Class 42)
	  	3,716,936	  	11/24/2009	  	78/449,977	  	07/13/2004
	 US
	  	  
 ACUSYST-MAXIMIZER

(Class 9)
	  	2,379,677	  	8/22/2000	  	75/829,292	  	10/22/1999
	 US
	  	  
 ACUSYST-XCELL
 (Class 9)
	  	2,379,695	  	8/22/2000	  	75/831,709	  	10/26/1999
	 US
	  	  
 BIOVAXID (Class 5)
	  	3,112,639	  	7/4/2006	  	78/346,216	  	12/29/2003
	 EU
	  	  
 BIOVAXID (Class 5)  
	  	003605698	  	4/26/2005	  	003605698	  	01/09/2004

 SCHEDULE 2 

Patents 
  

									
	Country	  	Patent	  	Serial No.	  	Filing Date	  	 Product
 Line

	 	 	 	 	 
		  		  		  		  	
	 United States
	  	Basket-Type Bioreactor	  	08/946,884	  	10/8/1997	  	AutovaxID
	 United States
	  	Pressure Control System for a Bioreactor	  	07/779,082	  	10/18/1991	  	AutovaxID
	 United
States
	  	Method of Culturing Leukocytes  	  	08/233,547	  	4/26/1994	  	BiovaxID
	 United States
	  	Micro Hollow Fiber Bioreactor	  	08/970,332	  	11/14/1997	  	AutovaxID
	
EPO
	  	Extra-Capillary Fluid Cycling System and Method for a Cell Culture Device	  	EP07777189.7	  	5/21/2007	  	AutovaxID
	 AT
	  	Extra-Capillary Fluid Cycling System and Method for a Cell Culture
Device	  	07777189.7	  	5/21/2007	  	AutovaxID
	 CH
	  	Extra-Capillary Fluid Cycling System and Method for a Cell Culture Device	  	07777189.7	  	5/21/2007	  	AutovaxID
	 DE
	  	Extra-Capillary Fluid Cycling System and Method for a Cell Culture
Device	  	07777189.7	  	5/21/2007	  	AutovaxID
	
FR
	  	Extra-Capillary Fluid Cycling System and Method for a Cell Culture Device	  	07777189.7	  	5/21/2007	  	AutovaxID
	 GB
	  	Extra-Capillary Fluid Cycling System and Method for a Cell Culture
Device	  	07777189.7	  	5/21/2007	  	AutovaxID
	 United
States
	  	Extra-Capillary Fluid Cycling System and Method for a Cell Culture Device	  	12/274,971	  	11/20/2008	  	AutovaxID
	 EPO
	  	Method and System for the Production of Cells and Cell Products and
Applications Thereof	  	EP07777182.2	  	5/21/2007	  	AutovaxID
	 United
States
	  	Method and System for the Production of Cells and Cell Products and Applications Thereof	  	12/274,993	  	11/20/2008	  	AutovaxID
	 WIPO
	  	Methods for Inducing a Sustained Immune Response Against a B-Cell
Idiotype Using Autologous Anti-Idiotypic Vaccines	  	PCT/US2009/059880	  	10/7/2009	  	BiovaxID

									
	 WIPO
	  	Perfusion Bioreactors, Cell   Culture Systems, and Methods for Production of Cells
and Cell Products	  	PCT/US2009/061700	  	10/22/2009	  	AutovaxID

 SCHEDULE 3 
 Copyrights 
 None

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]